After watching a report on interference RNA on PBS NOVA show last year, I decided buy stock (RNAI) of SiRNA therapeutics that pioneered research in this exciting new technology. Interference RNA got a lot of press when 2006 Nobel prize for Medicine was awarded to Andrew Fire and Craig Mello, who discovered “RNA interference: gene silencing by double-stranded RNA”.
Sirna has partnered with several companies (GSK, Allergan, etc.) to develop therapies based on interference RNA. They have one therapy in phase II clinical trials and several others getting ready to start clinical trials.
Today, pharmaceutical company, Merck (MRK), annouced that they’ll buy Sirna for $1.1Billion, i.e. $13 per share (~200% profit for me, Ka-ching!!). Glaxo SmithKline (GSK), who is already partnering with Sirna to develope agents for respiratory targets, may make a counter bid to protect their investment. That means more Ka-ching for me and other Sirna stockholders. Ay-Caramba!
Possibly Related Posts: